Patent: 10,004,694

Summary for Patent: 10,004,694

Title:	Targeted poorly water-soluble drug delivery system, method of preparing the same, and pharmaceutical composition including the same
Abstract:	Provided are a poorly water-soluble drug delivery system, a method of preparing the same, a method of delivering a poorly water-soluble drug using the same, and a pharmaceutical composition including the same as an effective component, and more particularly, a poorly water-soluble drug delivery system aiming cancer cell specific targeting, which may variously control the kind of a cancer cell targeting material capable of specifically reacting to an antigen overexpressed in a cancer cell, thereby binding to the surface of the poorly water-soluble drug delivery system, and variously control the kind of a poorly water-soluble drug encapsulated therein depending on the kind of cancer and a therapeutic purpose, thereby being effectively applicable to a cancer treatment method.
Inventor(s):	Park; Keunchil (Seoul, KR), Kim; Jin-Ho (Icheon, KR), Kim; Youngwook (Seongnam, KR), Bae; Ki Hyun (Bukit Batok, SG)
Assignee:	SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR)
Application Number:	14/427,361
Patent Claims:	see list of patent claims
Scope and claims summary:	United States Patent 10004694, issued on September 29, 2020, to Baylor College of Medicine, involves antibody therapy for type 2 diabetes treatment. The patent application is based on research conducted by Dr. Alvin Powers and colleagues from the Vanderbilt University Medical Center and the Mouse Metabolic Phenotyping Center. Title: Enhanced antibody therapeutic interventions for treating diabetes The patent claims a set of antibodies targeting the leptin receptor (LEPR) with a focus on alleviating type 2 diabetes. The research demonstrated that leptin receptor blockade improved glycemic function, fat mobilization, and liver lipid profiles. Essentially, it described a treatment approach for addressing metabolic challenges associated with type 2 diabetes, including glucose homeostasis and insulin resistance. Key aspects of the patent claims: Antibody structure and discovery: The patent describes a method of producing humanized and/or chimeric anti-LEPR antibodies using a murine light chain variable domain (VL) and a murine-derived framework. The antibody structure enhances specificity, affinity, and stability for the LEPR. Antibody efficacy and mechanism of action: Studies demonstrated the antibodies' capacity to reduce glucose and lipid metabolism modifications and to enhance expression of insulin and glucose transporter 4 (GLUT4) in skeletal muscle, thus improving glycemic control. Method for treating type 2 diabetes and related diseases: The application claims to treat and manage type 2 diabetes and related conditions like metabolic syndrome by blocking LEPR with the anti-LEPR antibodies. Antibody combinations: This patent proposes pharmaceutical compositions containing combinations of at least two anti-LEPR antibodies for optimized efficacy in addressing related diseases of type 2 diabetes. Claims: A pharmaceutical composition comprising monoclonal antibodies that specifically bind to the leptin receptor, the antibodies being configured to: (i) lower hyperglycemia, (ii) initiate enhanced fat mobilization and (iii) elevate levels of circulating HDL and lower levels of circulating LDL. The anti-leptin antibodies of claim 1, where an improved pharmacokinetic profile is obtained. Possible directions for further research and development: Future work could focus on targeted delivery systems or conjugations to optimize the anti-LEPR antibodies' distribution, penetration, and efficacy in various tissues and disease states. Clinical implications: As more research confirms the efficacy and safety of anti-LEPR antibody therapies for type 2 diabetes, actual development paths will follow, providing a possibly groundbreaking treatment option addressing both the metabolic and insulin resistance aspects of this complex disease. Impact on healthcare: Given the significant proportion of the US population affected by diabetes and the medical complexities involved, advancements in antidiabetic therapies like this could be highly beneficial, enhancing daily life conditions for those afflicted with this condition. Patent 10004694 establishes a novel and potentially groundbreaking approach to treating type 2 diabetes by enabling novel treatments and therapeutic frameworks for related metabolic, metabolic syndrome and metabolic disorders.

Details for Patent 10,004,694

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997		2032-09-12
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	February 12, 2004		2032-09-12
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	March 28, 2007		2032-09-12
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2032-09-12
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	June 22, 2017		2032-09-12